Financial Analysis of Enterprises in Pharmaceutical Industry Based on the Harvard Analytical Framework —— Take TongRenTang, Guangzhou Baiyunshan, Yunnan Baiyao as Example
DOI:
https://doi.org/10.54097/dy2mr796Keywords:
Harvard Analytical Framework, Pharmaceutical enterprises, Financial analysis.Abstract
Under the pressure of aging population and impact of COVID-19, the importance of pharmaceutical industry cannot be neglected. This passage will utilize Harvard Analytical Framework to study the financial situation and development opportunities of three old public brands with analyzing information from their annual reports and East Money. Firstly, this passage will use PEST model to analyze the industrial advantages and disadvantages from four aspects, Politics, Economy, Society and Technology. Then this passage will focalize on specific analysis of companies, with accounting analysis and financial analysis. Compared with others, the pharmaceutical industry in China has little external interference. Generally, enterprises listed are promising and competitive. Despite a few adverse events, they all have good solvency and profitability. It will be the foundation of R&D. It is worth noting that with the support of government policies, the R&D of innovative drugs will be a crucial point in this thriving industry. This passage can be a reference for investors and managers of enterprises.
Downloads
References
Wu, Z. & Guo, H. An empirical analysis of the development opportunities of the pharmaceutical industry in the post-epidemic context. Co-Operative Economy & Science. 2023, (11), 30-33.
Shi, B., & Zhang, S. Research on financial risk analysis and control of pharmaceutical enterprises -- Taking Fosun Pharmaceutical as an example. China Market. 2023, (30), 93-96.
Zhang, X., & Zhong, Y. Financial Analysis of Pharmaceutical Company Based on the Harvard Analysis Framework—— Take data from the last five years of TongRenTang as an example. Management & Technology of SME. 2022, (17), 191-193.
Zhao, J. Study on the influence of centralized drug procurement with volume on pharmaceutical industry. Price Supervision and Anti-Monopoly in China. 2024, (02), 31-33.
Liu, T. Analysis and enlightenment of diversified investment strategy of Yunnan Baiyao. 2Business. 2015, (15), 115+88.
Wu, S. Weak growth, negative beset Baiyun Mountain to play a "good card". China Economic Weekly. 2022, (16), 68-69.
Zhou, D. The impact of profitability on exploratory innovation of firms. Times of Economy & Trade. 2024, 21 (02), 121-125.
Song, W., & Cai W. Analysis and evaluation of solvency of municipal companies. Journal of Chongqing University of Science and Technology (Social Sciences Edition). 2013, (12), 67-69.
Yang, X. Research on the changing trend of cost and expense structure of drug enterprises -- based on the analysis of data of listed drug enterprises in the past ten years. Price: Theory & Practice. 2023, (11), 121-123+214.
Ma, H., & Li, Y. Research on profit quality evaluation method of pharmaceutical manufacturing enterprises considering profit formation process. Science & Technology Ecnony Market. 2021, (02), 31-32+34.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.